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Obesity and related disorders, including hypertension and type 2
diabetes, are associated with heightened risk of cardiovascular disease.
Endothelin (ET )-1, the most potent vasoconstrictor peptide, also
possesses important properties to stimulate the development and
progression of the atherosclerotic process. It is therefore conceivable
that increased ET-1 activity might participate in the derangement of
adiposity-related vascular homeostasis. This concept is supported by
the results of studies using receptor antagonists to show that the activity
of endogenous ET-1 is indeed enhanced in overweight and obesity, as
well as in type 2 diabetes. Also, increased ET-1 contributes to endothelial
dysfunction related to obesity and type 2 diabetes, whereas decreasing
ET-1 vasoconstrictor tone corrects the defect of endothelium-dependent
vasodilation in these patients. Furthermore, ET-1-dependent forearm
vasoconstriction is increased in overweight and obese, but not in lean
hypertensive patients. In addition, in patients with central adiposity and
the metabolic syndrome, enhanced intravascular ET-1 activity coexists
with decreased nitric oxide (NO)-dependent vasodilator capacity, sug-
gesting a prevalence of vasoconstrictor mediators in obese vessels. One
of the mechanisms evoked to explain the development of vascular
abnormalities in obesity deals with the physiological endothelial effects
of insulin and their derangement in insulin-resistant states. Thus, in
addition toNO-dependent vasodilator properties, insulin also stimulates
ET-1 production. This action has been demonstrated by use of antag-
onists of ET-1 receptors in the forearm circulation of healthy subjects,
where ET-1-dependent vasoconstriction is increased following local
infusion of insulin and accompanies a concurrent rise in NO-mediated
vasodilation. In the healthy state, therefore, there is a balance between
insulin-stimulated release of ET-1 and NO, with a resulting neutral
hemodynamic response to the hormone. In conditions of caloric excess
and adiposity, by contrast, insulin resistance implies defective insulin-
mediated vasodilation, leading in turn to impaired ability of the
hormone to enhance its delivery and that of substrates to peripheral
tissues. An important role of ET-1 in this abnormality is supported by
studies showing that upregulation of the ET-1 system impairs NO-
mediated vasodilation in the vessels of insulin-resistant patients with
obesity or type 2 diabetes, whereas NO bioactivity is restored following
blockade of ET-1 receptors. This notion is further strengthened by the
observation that ET-1 receptor antagonism improves insulin sensitivity
in obese patients with insulin resistance. In conclusion, considerable
evidence supports a mechanistic role of ET-1 in the pathophysiology of
adiposity-related vascular dysfunction. Given the link between higher
ET-1 activity and obesity, targeting the ET-1 system has hence the
potential for effective cardiovascular prevention in this condition.
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Background: Endothelin-1 (ET-1) attenuates insulin-stimulated
glucose uptake in human skeletal muscle, leading to the development
of insulin resistance. However, the molecular mechanism underlying
negative regulation of insulin receptor signaling by ET-1 remains un-
clear. The purpose of this study was to determine the inhibitory effects
of ET-1 on insulin-induced Akt phosphorylation in rat skeletal muscle
(L6) cells. Methods: Western blot experiments were used to analyze
changes in the phosphorylation levels of Akt at threonine 308 (Thr308)
and serine 473 (Ser473). mRNA expression for two ET receptors (ETAR
and ETBR) and the C-terminus region of G protein-coupled receptor
kinase 2 (GRK2-ct) were detected by reverse transcription polymerase
chain reaction. GRK2-ctwas overexpressed in L6 cells using adenovirus-
mediated gene transfer. Results: mRNAs for ETAR and ETBR were
detected on L6 cells as well as on human skeletal muscle. Insulin
induced sustained Akt phosphorylation at Thr308 and Ser473, which
was completely abolished by a phosphatidylinositol 3-kinase (PI3K)
inhibitor, LY294002. The insulin-induced phosphorylation of Akt was
suppressed by addition of ET-1 after insulin stimulation. The inhibitory
effect of ET-1 was counteracted by a Gαq/11 protein inhibitor, YM-
254890, and by a selective ETAR antagonist, BQ-123. Overexpression
of GRK2-ct to interfere with the function of endogenously expressed
GRK2 canceled the ET-1-induced suppression of insulin-stimulated Akt
phosphorylation. Conclusions: ETAR activation with ET-1 suppresses
insulin-induced, PI3K-medaited phosphorylation of Akt at Thr308 and
Ser473 in a GRK2-dependent manner in skeletal muscle. These results
indicate that both ETAR and GRK2 are therapeutic targets for insulin
resistance and type 2 diabetes.
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